Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-10-05 Legal Proceedings Report
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure announces new Cevira patent in Europe
Legal Proceedings Report Classification · 99% confidence The document is a press release from Photocure ASA dated October 5, 2020, announcing that the European Patent Office (EPO) granted a new patent (EP 2983780) for their Cevira device. This type of announcement, detailing specific corporate developments, legal/IP updates, or business milestones outside of routine financial reporting (like earnings or annual reports), typically falls under general Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if it were about a lawsuit. Since it is a patent grant announcement, which is a specific corporate action/update, and it doesn't fit the definitions for ER, 10-K, IR, or DIV, the most appropriate general category for non-standard corporate news is RNS (Regulatory Filings/Announcements). Given the short length and the nature of the announcement (a specific event update), RNS is the best fit among the provided options, as it is not a formal financial report or a management change.
2020-10-05 English
Photocure announces new Cevira patent in Europe
Regulatory Filings Classification · 95% confidence The document is a short press release dated October 5, 2020, announcing that the European Patent Office granted a new patent (EP 2983780) for Photocure's Cevira device. It contains key business updates (patent grant, licensing agreement details) but is not a comprehensive financial report (like 10-K or IR), a formal earnings release (ER), or a transcript (CT). Since it is a specific, non-financial regulatory/business update that doesn't fit the other specific categories (like DIRS, DIV, MANG), it falls best under the general 'Regulatory Filings' category (RNS) as a general corporate announcement, or potentially a Legal Proceedings Report (LTR) due to the patent nature, but RNS is the broader fit for general news releases not covered elsewhere. Given the content is a specific announcement of a legal/IP event, RNS is the most appropriate fallback for a non-standard announcement.
2020-10-05 English
Photocure launches European Hexvix operations
Regulatory Filings Classification · 95% confidence The document is a press release dated October 1, 2020, announcing the commencement of sales, marketing, and distribution of Hexvix® in European markets previously operated by Ipsen. It details a transaction, confirms financial targets related to the acquired rights, and discusses business strategy and operational milestones. This type of announcement, focusing on a significant business event (acquisition/launch) and confirming financial outlooks, is characteristic of a general corporate update or earnings-related news, but it is not a full financial report (10-K or IR), a formal earnings release (ER) which usually contains summarized P&L/Balance Sheet figures, nor a management discussion (MDA) which is typically part of a larger report. Since it is a specific announcement about a major operational/financial event and confirms targets, it most closely aligns with a general corporate announcement that might accompany or precede a formal filing. Given the options, it is a significant corporate event announcement. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a capital change (CAP/SHA). It is a press release detailing business progress and financial expectations following a transaction. This fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standardized corporate disclosure, or potentially an Earnings Release (ER) if it were quarterly results, but here it's focused on a specific operational launch and transaction confirmation. Given the content is a news release about a business launch and financial targets confirmation, and it's not a standard regulatory form like 10-K or IR, RNS is the most appropriate fallback for a significant, non-standardized corporate press release.
2020-10-01 English
Photocure launches European Hexvix operations
Regulatory Filings Classification · 95% confidence The document is a press release dated October 1, 2020, announcing that Photocure ASA has commenced the sales, marketing, and distribution of Hexvix® in European markets previously managed by Ipsen. It details the strategic importance of this operational launch and confirms key financial targets related to the acquired rights. This type of announcement, focusing on a significant business event (launch of operations, acquisition details, financial outlook confirmation) but not being a full statutory report (like 10-K or IR) or a formal regulatory filing notification, best fits the category for general business updates or announcements. Since it is not a formal Earnings Release (ER) which focuses purely on period results, nor a specific capital change (CAP/SHA), nor a management change (MANG), it is best classified as a general Regulatory Filing (RNS) as it is a public announcement of a material business event, or potentially a Capital/Financing Update (CAP) due to the financial details, but the primary focus is the operational launch. Given the options, RNS serves as the best general regulatory announcement fallback for significant corporate news that doesn't fit a more specific operational/financial code. However, since it confirms financial targets related to a transaction, it has strong elements of a business update. Since it is not a formal report, RNS is the most appropriate general classification for this type of press release.
2020-10-01 English
Photocure ASA - Share option grant and sale of shares
Remuneration Information Classification · 99% confidence The document announces the granting of share options to employees and a sale of own shares to an employee, detailing the number of options, exercise prices, and resulting holdings for primary insiders (executives/directors). This type of disclosure, specifically reporting personal share transactions by company directors and executives (insider trades) or transactions in own shares by the company involving employees/insiders, strongly aligns with the definition of Director's Dealing (DIRS) or Transaction in Own Shares (POS). Since the primary focus is on the allocation of options and subsequent holdings of key management, DIRS is highly relevant. However, the document explicitly mentions the sale of 'own shares' (POS) and the granting of options which are often treated as insider transactions (DIRS). Given the detailed breakdown of option grants to primary insiders and the explicit mention of a sale of own shares, the most specific category covering insider transactions related to equity compensation is Director's Dealing (DIRS). If DIRS was not available, POS would be a strong secondary choice. Since DIRS covers transactions by directors/executives, and this document details option grants to the CEO, CFO, and other VPs, DIRS is the best fit for the insider activity described.
2020-09-15 English
Photocure ASA - Share option grant and sale of shares
Share Issue/Capital Change Classification · 99% confidence The document explicitly details the granting of share options to employees and primary insiders, including the CEO and CFO, and also reports a transaction involving the sale of own shares to an employee. This content directly relates to insider transactions and executive compensation/incentive programs. While it involves share transactions (POS) and remuneration details (DEF 14A), the core focus is on reporting personal share transactions by directors and executives (insider trades) following the option grant. This aligns most closely with the Director's Dealing (DIRS) category, which covers reports of personal share transactions by company directors and executives (insider trades). The document is a direct announcement of these transactions, not a general regulatory filing (RNS) or a formal remuneration report (DEF 14A).
2020-09-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.